NCT04175301 is a Phase 2 clinical trial of Hydrogen in Malignant Glioma, sponsored by Stony Brook University.

Who is sponsoring NCT04175301?

NCT04175301 is sponsored by Stony Brook University.

What drugs are being tested in NCT04175301?

Interventions in NCT04175301: Hydrogen, Placebo oral tablet.

What condition does NCT04175301 study?

NCT04175301 studies Malignant Glioma.

Is NCT04175301 still recruiting?

NCT04175301 is currently active, enrolled. Last updated 29 July 2025.

Last reviewed 2025-07-29 · How we verify

NCT04175301

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.

Active, enrolled Phase 2 Last updated 29 July 2025

What this trial tests

Phase 2 trial testing Hydrogen in Malignant Glioma in 15 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

31 October 2019

Primary endpoint
5 September 2026

30 September 2027

Quick facts

Lead sponsor	Stony Brook University
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	15
Start date	31 October 2019
Primary completion	5 September 2026
Estimated completion	30 September 2027
Sites	1 location across United States

Drugs / interventions tested

Hydrogen — full drug profile →
Placebo oral tablet — full drug profile →

Conditions studied

Malignant Glioma — all drugs for Malignant Glioma →

Sponsor

Stony Brook University

Who can join

18 and older, any sex, with Malignant Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot randomized control trial (RCT) to explore the effects of hydrogen rich water on quality of life in patients with high grade gliomas, receiving focal radiation therapy to the brain concurrent with chemotherapy with Temozolomide.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hydrogen

Trials testing the same drug.

NCT05574296 — Hydrogen's Feasibility and Safety as a Therapy in ECPR · Phase 1 · recruiting
NCT05196295 — To Evaluate the Safety of Treating Rheumatologic and Metabolic Patients With Molecular Hydrogen Supplement. · Phase 1 · unknown
NCT05116215 — To Evaluate the Safety of Treating Autoimmune Diseases With Molecular Hydrogen Supplement · Phase 1 · unknown
NCT04046211 — Safety of Inhaled Hydrogen Gas Mixtures in Healthy Volunteers · Phase 1 · completed
NCT03971617 — Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease · Phase 2, PHASE3 · terminated

Other recruiting trials for Malignant Glioma

Currently open trials in the same condition.

NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07447531 — T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas · NA · recruiting
NCT06470711 — Mapping of Electrical Properties in the Brain · recruiting
NCT05717153 — Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma · EARLY_PHASE1 · recruiting
NCT05030298 — Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial · Phase 1 · recruiting

Other Stony Brook University trials

Trials by the same sponsor.

NCT07478250 — First Responder Safety Training (FiRST) · NA · not yet recruiting
NCT07076342 — The Role of mGluR5 in CBT-I · Phase 4 · recruiting
NCT07009691 — Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS · NA · recruiting
NCT07114900 — Randomized Controlled Physical Activity App Intervention for Black Women · Phase 3 · active not recruiting
NCT05245227 — Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04175301 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stony Brook University
Last refreshed: 29 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04175301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing